BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer ; volume:8 ; number:1 ; day:21 ; month:11 ; year:2023 ; pages:1-4 ; date:12.2023
npj vaccines ; 8, Heft 1 (21.11.2023), 1-4, 12.2023
- Creator
-
Valanparambil, Rajesh M.
Lai, Lilin
Johns, Margaret A.
Davis-Gardner, Meredith
Linderman, Susanne L.
McPherson, Tarrant Oliver
Chang, Andres
Akhtar, Akil
Gamarra, Estefany L. Bocangel
Matia, Hayley
McCook-Veal, Ashley A.
Switchenko, Jeffrey
Nasti, Tahseen H.
Green, Felicia
Saini, Manpreet
Wieland, Andreas
Pinsky, Benjamin A.
Solis, Daniel
Dhodapkar, Madhav V.
Carlisle, Jennifer
Ramalingam, Suresh
Ahmed, Rafi
Suthar, Mehul S.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41541-023-00779-8
- URN
-
urn:nbn:de:101:1-2024021209572242643278
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Valanparambil, Rajesh M.
- Lai, Lilin
- Johns, Margaret A.
- Davis-Gardner, Meredith
- Linderman, Susanne L.
- McPherson, Tarrant Oliver
- Chang, Andres
- Akhtar, Akil
- Gamarra, Estefany L. Bocangel
- Matia, Hayley
- McCook-Veal, Ashley A.
- Switchenko, Jeffrey
- Nasti, Tahseen H.
- Green, Felicia
- Saini, Manpreet
- Wieland, Andreas
- Pinsky, Benjamin A.
- Solis, Daniel
- Dhodapkar, Madhav V.
- Carlisle, Jennifer
- Ramalingam, Suresh
- Ahmed, Rafi
- Suthar, Mehul S.
- SpringerLink (Online service)
Other Objects (12)
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
Bivalent single domain antibody constructs for effective neutralization of Venezuelan equine encephalitis
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
Bivalent single domain antibody constructs for effective neutralization of Venezuelan equine encephalitis
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine
Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
Enhancement of Omicron-specific immune responses following bivalent COVID-19 booster vaccination in patients with chronic lymphocytic leukaemia
Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
Bivalent single domain antibody constructs for effective neutralization of Venezuelan equine encephalitis
Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Limited cross-variant neutralization after primary Omicron infection: consideration for a variant-containing booster
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant